Effects of endothelial cell proliferation and migration rates in a computational model of sprouting angiogenesis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Norton, Kerri Ann ^a   Popel, Aleksander S ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGIOGENIC THERAPY; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; MODEL; SPROUTING; VASCULARIZATION; ANGIOGENESIS; CELL MOTION; CYTOLOGY; HUMAN; METABOLISM; THEORETICAL MODEL; UMBILICAL VEIN ENDOTHELIAL CELL;

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN A;

CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MODELS, THEORETICAL; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84995514154     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36992     Document Type: Article

References (60)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
3. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nature reviews. Drug discovery 6, 273-286 (2007).
4. Chappell, J. C., Wiley, D. M. & Bautch, V. L. Regulation of blood vessel sprouting. Seminars in cell & developmental biology 22, 1005-1011 (2011).
5. Claesson-Welsh, L. & Welsh, M. VEGFA and tumour angiogenesis. Journal of internal medicine 273, 114-127 (2013).
6. Chung, A. S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nature reviews. Cancer 10, 505-514 (2010).
7. Vempati, P., Popel, A. S. & Mac Gabhann, F. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine & growth factor reviews 25, 1-19 (2014).
8. Blanco, R. & Gerhardt, H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harbor perspectives in medicine 3, a006569 (2013).
9. Vasudev, N. S. & Reynolds, A. R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17, 471-494 (2014).
10. Noren, D. P. et al. Endothelial cells decode VEGF-mediated Ca2+ signaling patterns to produce distinct functional responses. Science signaling 9, ra20 (2016).
11. Lee, E., Rosca, E. V., Pandey, N. B. & Popel, A. S. Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. The international journal of biochemistry & cell biology 43, 1812-1821 (2011).
12. Rosca, E. V. et al. A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer. PloS one 9, e111901 (2014).
13. Norton, K. A., Popel, A. S. & Pandey, N. B. Heterogeneity of chemokine cell-surface receptor expression in triple-negative breast cancer. American journal of cancer research 5, 1295-1307 (2015).
14. Noren, D., Rekhi, R., Long, B. & Qutub, A. A. In Vascularization: Regenerative Medicine and Tissue Engineering. (ed. E. M. Brey) 213 (2014).
15. Peirce, S. M., Mac Gabhann, F. & Bautch, V. L. Integration of experimental and computational approaches to sprouting angiogenesis. Current opinion in hematology 19, 184-191 (2012).
16. Enderling, H. & Rejniak, K. A. Simulating cancer: computational models in oncology. Frontiers in oncology 3 (2013).
17. Finley, S. D., Chu, L.-H. & Popel, A. S. Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug discovery today 20, 187-197 (2015).
18. Stefanini, M. O., Qutub, A. A., Mac Gabhann, F. & Popel, A. S. Computational models of VEGF-associated angiogenic processes in cancer. Mathematical Medicine and Biology dqq025 (2011).
19. Vilanova, G., Colominas, I. & Gomez, H. Capillary networks in tumor angiogenesis: from discrete endothelial cells to phase-field averaged descriptions via isogeometric analysis. International journal for numerical methods in biomedical engineering 29, 1015-1037 (2013).
20. Daub, J. T. & Merks, R. M. A cell-based model of extracellular-matrix-guided endothelial cell migration during angiogenesis. Bulletin of mathematical biology 75, 1377-1399 (2013).
21. Kim, M., Gillies, R. J. & Rejniak, K. A. Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol 3, 278 (2013).
22. Tang, L. et al. Computational modeling of 3D tumor growth and angiogenesis for chemotherapy evaluation. PloS one 9, e83962 (2014).
23. Magdoom, K. N. et al. MRI-based computational model of heterogeneous tracer transport following local infusion into a mouse hind limb tumor. PloS one 9, e89594 (2014).
24. Gevertz, J. Optimization of vascular-targeting drugs in a computational model of tumor growth. Physical review. E, Statistical, nonlinear, and soft matter physics 85, 041914 (2012).
25. Spill, F., Guerrero, P., Alarcon, T., Maini, P. K. & Byrne, H. M. Mesoscopic and continuum modelling of angiogenesis. Journal of mathematical biology 70, 485-532 (2014).
26. Burke, D. & Kelly, D. J. A mechanobiological model of endothelial cell migration and proliferation. Computer methods in biomechanics and biomedical engineering 19, 74-83 (2016).
27. Santos-Oliveira, P. et al. The Force at the Tip-Modelling Tension and Proliferation in Sprouting Angiogenesis. PLoS Comput Biol 11, e1004436 (2015).
28. Bazmara, H. et al. The Vital Role of Blood Flow-Induced Proliferation and Migration in Capillary Network Formation in a Multiscale Model of Angiogenesis. PloS one 10, e0128878 (2015).
29. Liu, G., Qutub, A. A., Vempati, P., Mac Gabhann, F. & Popel, A. S. Module-based multiscale simulation of angiogenesis in skeletal muscle. Theor Biol Med Model 8, 1-26 (2011).
30. Qutub, A. A. & Popel, A. S. Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting. BMC Syst Biol 3, 13 (2009).
31. Finley, S. D. & Popel, A. S. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. Journal of the National Cancer Institute 105, 802-811 (2013).
32. Tan, W. H., Popel, A. S. & Mac Gabhann, F. Computational model of Gab1/2-dependent VEGFR2 pathway to Akt activation. PloS one 8, e67438 (2013).
33. Finley, S. D., Angelikopoulos, P., Koumoutsakos, P. & Popel, A. S. Pharmacokinetics of Anti-VEGF Agent Aflibercept in Cancer Predicted by Data-Driven, Molecular-Detailed Model. CPT: pharmacometrics & systems pharmacology 4, 641-649 (2015).
34. Finley, S. D. & Popel, A. S. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. The AAPS journal 14, 500-509 (2012).
35. Qutub, A. A. & Popel, A. S. Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting. BMC systems biology 3, 13 (2009).
36. Koskimaki, J. E. et al. Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth. Transl Oncol 5, 92-97 (2012).
37. Lee, E., Koskimaki, J. E., Pandey, N. B. & Popel, A. S. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia 15, 112-IN116 (2013).
38. Mac Gabhann, F., Qutub, A. A., Annex, B. H. & Popel, A. S. Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2, 694-707 (2010).
39. Stamatelos, S. K., Kim, E., Pathak, A. P. & Popel, A. S. A bioimage informatics based reconstruction of breast tumor microvasculature with computational blood flow predictions. Microvascular research 91, 8-21 (2014).
40. Azegrouz, H., Trucco, E., Dhillon, B., MacGillivray, T. & MacCormick, I. J. Thickness dependent tortuosity estimation for retinal blood vessels. Conference proceedings: ⋯ Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 1, 4675-4678 (2006).
41. Anagnostou, A., Lee, E. S., Kessimian, N., Levinson, R. & Steiner, M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 87, 5978-5982 (1990).
42. Marin, V., Kaplanski, G., Gres, S., Farnarier, C. & Bongrand, P. Endothelial cell culture: protocol to obtain and cultivate human umbilical endothelial cells. Journal of immunological methods 254, 183-190 (2001).
43. Negre-Aminou, P. et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochimica et biophysica acta 1345, 259-268 (1997).
44. Frye, C. A. & Patrick, C. W., Jr. Isolation and culture of rat microvascular endothelial cells. In vitro cellular & developmental biology. Animal 38, 208-212 (2002).
45. Snead, M. D., Papapetropoulos, A., Carrier, G. O. & Catravas, J. D. Isolation and culture of endothelial cells from the mesenteric vascular bed. Methods in cell science 17, 257-262 (1995).
46. Zheng, B. et al. Human myogenic endothelial cells exhibit chondrogenic and osteogenic potentials at the clonal level. Journal of orthopaedic research: official publication of the Orthopaedic Research Society 31, 1089-1095 (2013).
47. Kim, E. et al. Multiscale imaging and computational modeling of blood flow in the tumor vasculature. Annals of biomedical engineering 40, 2425-2441 (2012).
48. Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nature reviews. Drug discovery 10, 417-427 (2011).
49. Goel, S., Wong, A. H. & Jain, R. K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harbor perspectives in medicine 2, a006486 (2012).
50. Goel, S. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiological reviews 91, 1071-1121 (2011).
51. Gacche, R. N. & Meshram, R. J. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846, 161-179 (2014).
52. Huang, Y., Stylianopoulos, T., Duda, D. G., Fukumura, D. & Jain, R. K. Benefits of vascular normalization are dose and time dependent-letter. Cancer research 73, 7144-7146 (2013).
53. Lee, E. et al. Inhibition of breast cancer growth and metastasis by a biomimetic peptide. Scientific reports 4, 7139 (2014).
54. Jackson, T. & Zheng, X. A cell-based model of endothelial cell migration, proliferation and maturation during corneal angiogenesis. Bulletin of mathematical biology 72, 830-868 (2010).
55. Thurston, G., Noguera-Troise, I. & Yancopoulos, G. D. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nature reviews. Cancer 7, 327-331 (2007).
56. Miles, K. M. et al. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PloS one 9, e112371 (2014).
57. Plank, M. J. & Sleeman, B. D. A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. Mathematical medicine and biology: a journal of the IMA 20, 135-181 (2003).
58. Milde, F., Bergdorf, M. & Koumoutsakos, P. A hybrid model for three-dimensional simulations of sprouting angiogenesis. Biophysical journal 95, 3146-3160 (2008).
59. Karagiannis, E. D. & Popel, A. S. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. Journal of theoretical biology 238, 124-145 (2006).
60. Jakobsson, L. et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nature cell biology 12, 943-953 (2010).